GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immuron Limited
Immuron is an Australian biopharmaceutical company. Its share price reflects its focus on developing oral therapies to prevent infectious diseases. The chart is driven by news of clinical trials and commercial partnerships.
Share prices of companies in the market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal diseases. We have classified it in the Pharma: Gastrointestinal segment. The chart below shows the market valuation for this segment.
Broad Market Index - GURU.Markets
Immuron is an Australian biotech company developing oral antibody-based therapies to protect against gastrointestinal infections. Its unique platform makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Immuron compares to it.
Change in the price of a company, segment, and market as a whole per day
IMRN - Daily change in the company's share price Immuron Limited
For Immuron Limited, a gastrointestinal health company, daily volatility reflects its sensitivity to product sales and clinical trial data. This metric is an important element of analysis in this niche.
Daily change in the price of a set of shares in a market segment - Pharma git
Immuron shares, which operate in the gastrointestinal immunotherapy niche, have their own unique fluctuations. The chart below shows the average daily volatility for this narrow biotech segment. It allows you to compare how IMRN's stock performance differs from the average "pulse" of companies with similar specializations.
Daily change in the price of a broad market stock, index - GURU.Markets
Immuron is an Australian biotech company developing drugs for the treatment of gastrointestinal diseases. Its shares bring the dynamism of this cutting-edge medical field to the US market, adding an international dimension to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immuron Limited
Immuron Limited's year-over-year performance tells the story of its unique platform for creating oral antibodies. Its market capitalization growth over the past 12 months reflects both sales of its commercial product, Travelan, for the prevention of traveler's diarrhea, and progress in clinical trials of its drugs for the treatment of more serious gastrointestinal diseases.
Annual dynamics of market capitalization of the market segment - Pharma git
Immuron Limited is an Australian biopharmaceutical company specializing in the development of oral medications for the treatment of gastrointestinal diseases. This chart shows how its unique technology and product commercialization successes are impacting its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immuron, which develops oral medications for gut health, is a niche biotech company. Its performance relative to the market demonstrates the level of investor confidence in its unique approach. Success in this niche could lead to significant growth, as it addresses problems neglected by larger players.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immuron Limited
Immuron is an Australian biotech company developing gastrointestinal health products. Its monthly performance reflects both sales of its commercial product, Travelan, and progress in clinical trials of new drugs.
Monthly dynamics of market capitalization of the market segment - Pharma git
Immuron is an Australian biotech company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal diseases such as traveler's diarrhea. The chart below illustrates the dynamics of the biotech sector, where the company occupies a unique niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immuron is an Australian biotech company developing drugs for the treatment of gastrointestinal diseases. Its shares are driven by news of its commercial product sales and research results. These dynamics are determined by local and industry factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immuron Limited
Immuron is an Australian biopharmaceutical company developing drugs for the treatment of gastrointestinal diseases. Its weekly stock price is driven by the results of clinical trials and the commercial success of its products.
Weekly dynamics of market capitalization of the market segment - Pharma git
Immuron Limited develops gastrointestinal health products. The chart compares the weekly stock performance of this niche company with the broader pharmaceutical sector. Does its niche allow it to chart a trajectory independent of global industry trends?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Immuron Limited is a pharmaceutical company whose stock follows the rhythm of news about clinical trials and partnerships. The chart clearly shows how its weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
IMRN - Market capitalization of the company Immuron Limited
Immuron Limited's stock price is a bet on a new approach to treating infections. This Australian biotech's market cap reflects investors' faith in its colostrum-based antibody-based drugs for the prevention of traveler's diarrhea and the treatment of liver disease.
IMRN - Share of the company's market capitalization Immuron Limited within the market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal diseases. Within its segment, its market capitalization reflects the uniqueness of its platform. The company's market capitalization is an indicator of the commercial success of its drug for travelers' diarrhea and the potential for other developments.
Market capitalization of the market segment - Pharma git
Immuron develops drugs to protect against gastrointestinal infections. How big is this niche? The graph below shows the overall market capitalization of this pharmaceutical sector. Its dynamics reflect the need for new methods to prevent and treat traveler's diarrhea and other intestinal infections.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Immuron chart visualizes a unique approach to treating gastrointestinal diseases. The Australian company's market capitalization is based on its platform for creating oral antibodies to prevent traveler's diarrhea and combat bacterial infections. This diagram illustrates a niche but exciting market.
Book value capitalization of the company, segment and market as a whole
IMRN - Book value capitalization of the company Immuron Limited
The book value of the Australian company Immuron is comprised of its production facilities for bovine colostrum-based gastrointestinal health products, as well as its R&D labs. The chart below shows how the value of this unique biotech production facility has changed.
IMRN - Share of the company's book capitalization Immuron Limited within the market segment - Pharma git
Immuron Limited is an Australian biopharmaceutical company. Its unique assets include the manufacturing facilities for its bovine colostrum-based gut health products. The chart shows the company's control over this specific biological manufacturing infrastructure.
Market segment balance sheet capitalization - Pharma git
Immuron is an Australian biopharmaceutical company. The pharmaceutical industry, as the chart shows, is capital-intensive. Immuron is a vertically integrated player. It owns the technology and manufacturing facilities to create colostrum-based antibody-based drugs.
Book value of all companies included in the broad market index - GURU.Markets
Immuron's assets are not factories, but a scientific platform for developing oral antibody-based drugs for the prevention and treatment of gastrointestinal diseases. Its book value reflects its scientific potential and the commercial infrastructure for its already approved product.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immuron Limited
Immuron is an Australian biotech company developing colostrum-based antibody-based therapies for the prevention and treatment of gastrointestinal diseases. Its value lies in its unique platform. The chart shows how the market values its commercial product and pipeline.
Market to book capitalization ratio in a market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing treatments to protect against gastrointestinal infections. Its valuation depends on the success of its products. The chart shows how the market views its unique technology platform and commercial prospects.
Market to book capitalization ratio for the market as a whole
Immuron Limited is an Australian biopharmaceutical company. Its market valuation is based on its unique technology platform and the potential of its products. This chart illustrates how even small biotech companies can achieve high valuations based on their intellectual property rather than tangible assets.
Debts of the company, segment and market as a whole
IMRN - Company debts Immuron Limited
Immuron is an Australian biopharmaceutical company developing antibody-based therapies for the treatment of gastrointestinal diseases. Commercializing such niche products may require targeted marketing and investment in manufacturing. This chart shows how the company funds its development and marketing of its unique therapies.
Market segment debts - Pharma git
Immuron is an Australian biotech company developing colostrum-based antibody-based treatments for gastrointestinal diseases. The company has products on the market but also invests in R&D. This chart shows how it balances commercial activities with scientific research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immuron Limited
Immuron Limited is an Australian biopharmaceutical company. This chart shows its financial structure. For a company with both marketed products and development pipelines, debt levels help assess the balance between current operations and future investments. Growing debt requires attention to R&D success.
Market segment debt to market segment book capitalization - Pharma git
Immuron is an Australian biopharmaceutical company developing colostrum-based antibody-based therapies for the treatment of gastrointestinal diseases. It offers a unique technology platform. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing how the company finances its niche but promising research.
Debt to book value of all companies in the market
Immuron Limited is an Australian biopharmaceutical company developing gastrointestinal health products. It has one commercial product and is also pursuing R&D. This chart provides context for assessing its financial strategy: how it uses sales revenue and investor capital to fund new clinical trials.
P/E of the company, segment and market as a whole
P/E - Immuron Limited
This chart shows the valuation of Immuron, an Australian biopharmaceutical company. The price-to-earnings ratio reflects sales of its commercial gastrointestinal health products, as well as the potential of its developments. This valuation represents a company that already has revenue, but whose future value depends on the success of its clinical trials.
P/E of the market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing and commercializing oral immunoglobulins for the treatment of gastrointestinal diseases, including traveler's diarrhea. This chart shows the average valuation for the sector, helping to understand how the market views this niche therapeutic platform.
P/E of the market as a whole
Immuron is an Australian biotech company developing antibody-based therapies for gastrointestinal diseases. Its valuation depends on the success of its products. General market sentiment, reflected in this chart, has little impact on its business, which is driven by the specifics of its niche market and clinical trial results.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immuron Limited
Immuron is an Australian biopharmaceutical company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal infections. This chart reflects sales expectations for its commercial product, Travelan, and progress in clinical development.
%20P%2FE%20Immuron%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immuron-Limited&v=1772551322955 "Chart of the company's future (projected) P/E Immuron Limited")
Future (projected) P/E of the market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing oral medications to prevent and treat gastrointestinal infections. Its valuation, relative to other biotechs, reflects investor sentiment on its unique platform. This demonstrates whether investors believe in the commercial potential of its travel products.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-git&v=1772551322981 "Future (projected) P/E graph of the market segment - Pharma git")
Future (projected) P/E of the market as a whole
Immuron is an Australian biopharmaceutical company developing drugs to prevent and treat gastrointestinal diseases. Its products are based on antibodies derived from bovine colostrum. This chart shows the general investor appetite for risk and their attitude toward companies with unconventional but potentially effective technology platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772551323066 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immuron Limited
Immuron is an Australian biotech company developing colostrum-based antibody-based therapies for the treatment of gastrointestinal diseases. Financial results presented here are dependent on sales of its traveler's diarrhea product and the success of clinical trials.
Profit of companies in the market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing drugs for the prevention and treatment of gastrointestinal diseases. This chart shows the overall profitability of the gastrointestinal pharmaceutical sector, helping to understand the commercial potential in this area of medicine.
Overall market profit
Immuron is an Australian biopharmaceutical company developing drugs for the prevention and treatment of gastrointestinal diseases. Its success depends on the results of clinical trials and the commercialization of its products. It's a niche company, with little connection to the global economic cycles illustrated by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immuron Limited
Immuron is an Australian biotech company developing drugs for the prevention and treatment of gastrointestinal diseases. Its revenue forecast depends on the success of its products, particularly those for the prevention of traveler's diarrhea. This chart reflects analyst expectations for the commercial potential of its developments.
%20profit%20of%20the%20company%20Immuron%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immuron-Limited&v=1772551323437 "Graph of future (projected) profit of the company Immuron Limited")
Future (predicted) profit of companies in the market segment - Pharma git
Immuron is an Australian biotech company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal diseases, such as traveler's diarrhea. This chart shows forecasts for this segment, helping to assess the potential of their platform to address common but often overlooked health issues.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-git&v=1772551323445 "Graph of future (predicted) profits of companies in a market segment - Pharma git")
Future (predicted) profit of the market as a whole
This chart reflects the investment climate and consumer health spending. Immuron, which develops over-the-counter gastrointestinal health products, is dependent on both factors. Economic growth supports demand and facilitates capital raising for new research and marketing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772551323461 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immuron Limited
Immuron is an Australian company developing gastrointestinal health products. This chart shows how investors view its current sales and the potential for expanding its technology into new markets.
P/S market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal infections. This chart shows the average valuation in the pharmaceutical sector. It reflects investor expectations for Immuron's unique platform for protecting travelers and the military.
P/S of the market as a whole
Immuron Limited is an Australian biopharmaceutical company developing and commercializing antibody-based therapies for the treatment of gastrointestinal diseases. Its products are aimed at preventing traveler's diarrhea and other infections. This chart helps evaluate this niche pharmaceutical company with commercialized products.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immuron Limited
Immuron is an Australian biopharmaceutical company developing antibody-based therapies for the prevention and treatment of gastrointestinal diseases. Future revenue depends on the success of its products, such as Travelan. The chart reflects the market's assessment of the commercial potential of its platform.
%20P%2FS%20Immuron%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immuron-Limited&v=1772551323665 "The graph of the company's future (projected) P/S Immuron Limited")
Future (projected) P/S of the market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal infections, such as traveler's diarrhea. This chart shows how the market assesses the commercial potential of its niche products.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20git&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-git&v=1772551323696 "Future (projected) P/S market segment graph - Pharma git")
Future (projected) P/S of the market as a whole
This reflects the overall sentiment of pharmaceutical investors. For Immuron, an Australian company developing gastrointestinal health products, this indicates demand for specialized solutions. Market optimism is supporting interest in drugs for the prevention of traveler's diarrhea and the treatment of liver disease.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772551323729 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immuron Limited
Immuron is an Australian biopharmaceutical company developing and commercializing oral immunoglobulins for the prevention and treatment of gastrointestinal infections. This chart shows sales revenue for its Travelan and Protectyn products. The sales growth reflects demand for traveler's diarrhea prevention products.
Sales of companies in the market segment - Pharma git
Immuron Limited is an Australian biopharmaceutical company developing oral antibody-based therapies for the treatment of gastrointestinal diseases. This chart shows the dynamics in this segment. Immuron's products, such as Travelan, are aimed at preventing traveler's diarrhea, occupying a unique niche in the market.
Overall market sales
Immuron Limited is an Australian biopharmaceutical company developing drugs for the treatment of gastrointestinal diseases. Its success depends on clinical data and commercialization. This overall economic activity schedule influences global healthcare spending and interest in new therapeutic approaches.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immuron Limited
Immuron is an Australian biopharmaceutical company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal infections, such as traveler's diarrhea. This chart shows analysts' forecasts for the commercial success of its existing products and the potential of new developments.
%20sales%20of%20the%20company%20Immuron%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immuron-Limited&v=1772551323902 "Schedule of future (projected) sales of the company Immuron Limited")
Future (projected) sales of companies in the market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing oral medications to prevent and treat gastrointestinal infections. This chart shows expectations for the gastrointestinal-focused pharmaceutical sector, illustrating the potential demand for such developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-git&v=1772551323907 "Schedule of future (projected) sales of companies in the market segment - Pharma git")
Future (projected) sales of the market as a whole
Immuron Limited is an Australian biopharmaceutical company developing oral antibody-based therapies for the treatment of gastrointestinal diseases. Its success depends on the commercialization of its platform. This graph, reflecting overall consumer health spending, influences demand for over-the-counter and specialty digestive medications.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772551323928 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immuron Limited
Immuron is an Australian biopharmaceutical company developing gastrointestinal health treatments based on antibodies derived from bovine colostrum. This chart shows the profitability of this unique platform. Profitability depends on sales of its commercial product for the prevention of travelers' diarrhea and the success of its clinical programs.
Market segment marginality - Pharma git
Immuron Limited is an Australian biopharmaceutical company developing antibody-based therapies for the treatment of gastrointestinal diseases. This chart is important as an indicator of potential. It reflects the average profitability in the industry, illustrating the financial goals Immuron aspires to achieve if its products are successfully commercialized.
Market marginality as a whole
Immuron is an Australian biopharmaceutical company developing drugs to prevent and treat gastrointestinal infections. This overall market profitability curve does not impact its operations. Demand for its products, for example, among travelers, depends on global tourism activity and medical need.
Employees in the company, segment and market as a whole
Number of employees in the company Immuron Limited
Immuron is an Australian biotech company developing oral antibody-based therapies for the prevention and treatment of infectious diseases. This graph shows the small team commercializing their products and conducting new clinical trials.
Share of the company's employees Immuron Limited within the market segment - Pharma git
Immuron Limited is an Australian company developing oral antibody-based therapies for the prevention and treatment of gastrointestinal diseases. This chart shows the percentage of immunologists and gastroenterologists the company attracts in this niche market. It reflects its unique focus on protecting the health of travelers and others.
Number of employees in the market segment - Pharma git
Immuron is an Australian biopharmaceutical company developing drugs based on antibodies from bovine colostrum for the treatment and prevention of gastrointestinal diseases. This graph illustrates how innovation can come from the most unexpected fields, creating unique therapeutic platforms and requiring specialists at the intersection of immunology and food technology.
Number of employees in the market as a whole
Immuron Limited, an Australian company developing gastrointestinal health products, demonstrates the global nature of the biopharmaceutical industry. The presence of such foreign players in the US market enriches it and creates additional jobs. This chart reflects the combined employment generated by both local and international companies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immuron Limited (IMRN)
Immuron is an Australian biotech company producing gastrointestinal health products (such as Travelan). This chart reflects the value of its intellectual capital. Its key asset is its proprietary antibody production platform and its commercial products. The chart shows how the market values this unique technology and its market potential.
%20of%20the%20company%20Immuron%20Limited%20(IMRN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immuron-Limited-IMRN&v=1772551324464 "Chart of market capitalization per employee (in thousands of dollars) of the company Immuron Limited (IMRN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma git
Immuron Limited is an Australian biopharmaceutical company specializing in gastrointestinal health products. The chart shows how the market values their niche expertise per employee. This allows for a comparison of how valuable their focused strategy is compared to more diversified pharmaceutical companies.
%20by%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-git&v=1772551324472 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma git")
Market capitalization per employee (in thousands of dollars) for the overall market
Immuron Limited is an Australian biopharmaceutical company developing drugs for the treatment of gastrointestinal diseases. This chart shows the average value the market assigns to one employee, highlighting the importance of developments in this area.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772551324478 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immuron Limited (IMRN)
Immuron is an Australian biopharmaceutical company. They have a commercial product (Travelan) for the prevention of traveler's diarrhea. This graph shows how efficiently their small team generates revenue from sales of this niche, over-the-counter drug.
%20Chart%20Immuron%20Limited%20(IMRN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immuron-Limited-IMRN&v=1772551324494 "Company Profit Per Employee (in thousands of dollars) Chart Immuron Limited (IMRN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma git
Immuron Limited is an Australian biopharmaceutical company that develops and commercializes antibody-based therapies for the treatment of gastrointestinal diseases. Its business model combines sales of existing products with R&D. This chart shows how effectively the commercial division generates revenue to fund further research.
%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-git&v=1772551324528 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma git")
Profit per employee (in thousands of dollars) for the market as a whole
Immuron (IMRN) is an Australian biotech company commercializing Travelan (a supplement to prevent traveler's diarrhea) and developing the Hyperimmune platform for the treatment of gastrointestinal tract infections. This chart shows the market average profitability per employee. It helps assess how effectively IMRN utilizes its staff for commercialization and R&D in its niche.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772551324550 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immuron Limited (IMRN)
Immuron is an Australian biopharmaceutical company developing gastrointestinal health products. This chart demonstrates the effectiveness of its niche strategy in pharmaceuticals. It reflects how successfully the company sells its existing products and develops new ones, monetizing its scientific platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immuron-Limited-IMRN&v=1772551324555 "Sales chart per company employee Immuron Limited (IMRN)")
Sales per employee in the market segment - Pharma git
Immuron is an Australian biotech company developing oral antibody-based therapies for the treatment of gastrointestinal diseases. This chart shows the average revenue per employee in the segment. It helps assess how effectively the Immuron team commercializes its niche products compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Immuron is an Australian biotech company. They have one commercial product (Travelan) for the prevention of traveler's diarrhea, as well as R&D projects. This chart shows how efficiently their small team generates revenue from sales of their niche over-the-counter drug and from partner R&D programs.
Short shares by company, segment and market as a whole
Shares shorted by company Immuron Limited (IMRN)
Immuron is an Australian biotech company that produces supplements (Travelan) to prevent traveler's diarrhea and develops gastrointestinal medications. This chart highlights the market's perceived niche nature. The bears believe their core product is a dietary supplement, not a drug, and the company lacks any significant R&D.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immuron-Limited-IMRN&v=1772551324604 "Short Shares Chart for the Company Immuron Limited (IMRN)")
Shares shorted by market segment - Pharma git
Immuron Limited is an Australian biopharmaceutical company developing oral antibodies (derived from bovine colostrum) for the prevention and treatment of gastrointestinal diseases, such as traveler's diarrhea. This chart shows the overall short position in the gastrointestinal-focused biotech sector. Its rise signals investor skepticism about the commercial success of niche drugs.
Shares shorted by the overall market
Immuron is an Australian biotech company developing drugs for gut health and the fight against infections (such as traveler's diarrhea). This chart illustrates the general fear. When investors are afraid, they avoid foreign microcaps. They fear that IMRN won't have the capital for expensive trials and marketing, and they sell off the stock due to high risk and low liquidity.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immuron Limited (IMRN)
Immuron Limited is an Australian company that produces medications to protect against intestinal infections (such as traveler's diarrhea). It's a niche market. This indicator shows how investors react to sales reports or military contract news, indicating "overbought" (above 70) or "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immuron-Limited-IMRN&v=1772551324697 "RSI 14 indicator chart for the company's stock Immuron Limited (IMRN)")
RSI 14 Market Segment - Pharma git
Immuron Limited is an Australian biotech company developing oral antibody-based therapies to protect against gastrointestinal infections, such as traveler's diarrhea. This chart measures the overall momentum in the gastrointestinal biotech sector and helps determine whether the entire segment is overheated.
RSI 14 for the overall market
For Immuron, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMRN (Immuron Limited)
Immuron is an Australian biotech company developing antibody-based drugs (derived from bovine colostrum) for the treatment of gastrointestinal diseases, including traveler's diarrhea (Travelan). This chart shows the analysts' average 12-month forecast. It reflects their view on Travelan's commercial potential and R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMRN-Immuron-Limited&v=1772551324742 "A chart showing analyst consensus forecasts for the expected stock price. IMRN (Immuron Limited)")
The difference between the consensus estimate and the actual stock price IMRN (Immuron Limited)
Immuron is an Australian biotech company that produces antibody-based drugs (Travelan) (derived from bovine colostrum) to protect against traveler's diarrhea. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock's price and its target, reflecting their belief in this niche market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMRN-Immuron-Limited&v=1772551324776 "A chart showing the difference between the consensus forecast and the actual stock price. IMRN (Immuron Limited)")
Analyst consensus forecast for stock prices by market segment - Pharma git
Immuron is an Australian biotech focused on gastrointestinal health. Its flagship product (Travelan) is a dietary supplement for the prevention of "traveler's diarrhea." This chart displays analysts' overall expectations for the entire pharmaceutical (gastrointestinal) sector. It shows whether experts believe the digestive wellness market will grow.
Analysts' consensus forecast for the overall market share price
Immuron is an Australian biotech company that produces antibody-based drugs for gastrointestinal protection, most notably Travelan (for traveler's diarrhea). This chart shows overall market sentiment. For IMRN, whose business is a hybrid of "protection" (health) and "cyclicals" (travel), the overall optimism is important as it reflects the recovery of global travel.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immuron Limited
Immuron is an Australian biotech company with a single bet: oral (in tablet form) antibodies (derived from cow's milk) for the prevention of traveler's diarrhea (Travelan) and other gastrointestinal infections. This chart is a summary of their direct-to-consumer (D2C) medicine. It reflects their (low) sales and their (long) path to FDA approval for their niche product.
AKIMA Market Segment Index - Pharma git
Immuron (IMRN) is an Australian biopharmaceutical company. They produce oral immunoglobulins (Travelan), which prevent travelers' diarrhea by neutralizing bacteria in the gut. The chart shows the average index for the segment, helping investors assess the demand for this niche intestinal approach compared to the average.
The AKIM Index for the overall market
Immuron is an Australian biopharmaceutical company developing oral immunotherapies based on polyclonal antibodies (colostrum) for gut health. This chart, which reflects the market average, provides a macro backdrop. It helps assess how IMRN, which sells Travelan, compares to overall economic trends.
